Literature DB >> 22505523

Kallikrein-related peptidase signaling in colon carcinoma cells: targeting proteinase-activated receptors.

Hyunjae Chung1, Magda Hamza, Katerina Oikonomopoulou, Valérie Gratio, Mahmoud Saifeddine, G Duke Virca, Eleftherios P Diamandis, Morley D Hollenberg, Dalila Darmoul.   

Abstract

We hypothesized that kallikrein-related peptidase 14 (KLK14) is produced by colonic tumors and can promote tumorigenesis by activating proteinase-activated receptors (PARs). We found that KLK14 is expressed in human colon adenocarcinoma cells but not in adjacent cancer-free tissue; KLK14 mRNA, present in colon cancer, leads to KLK14 protein expression and secretion; and KLK14 signals viaPAR-2 in HT-29 cells to cause (1) receptor activation/internalization, (2) increases in intracellular calcium, (3) stimulation of ERK1/2/MAP kinase phosphorylation, and (4) cell proliferation. We suggest that KLK14, acting via PAR-2, represents an autocrine/paracrine regulator of colon tumorigenesis.

Entities:  

Mesh：

Substances：

Year:  2012        PMID： 22505523     DOI： 10.1515/bc-2011-231

Source DB:  PubMed          Journal:  Biol Chem        ISSN： 1431-6730            Impact factor:   3.915


  6 in total

1.  Discovery of Novel Nonpeptidic PAR2 Ligands.

Authors:  Ilona Klösel; Maximilian F Schmidt; Jonas Kaindl; Harald Hübner; Dorothee Weikert; Peter Gmeiner
Journal:  ACS Med Chem Lett       Date:  2020-05-22       Impact factor: 4.345

Review 2.  Proteinase-activated receptors (PARs) - focus on receptor-receptor-interactions and their physiological and pathophysiological impact.

Authors:  Frank Gieseler; Hendrik Ungefroren; Utz Settmacher; Morley D Hollenberg; Roland Kaufmann
Journal:  Cell Commun Signal       Date:  2013-11-11       Impact factor: 5.712

3.  Aberrant expression of kallikrein-related peptidase 7 is correlated with human melanoma aggressiveness by stimulating cell migration and invasion.

Authors:  Tiphaine Delaunay; Lydia Deschamps; Meriem Haddada; Francine Walker; Antoninus Soosaipillai; Feryel Soualmia; Chahrazade El Amri; Eleftherios P Diamandis; Maria Brattsand; Viktor Magdolen; Dalila Darmoul
Journal:  Mol Oncol       Date:  2017-08-11       Impact factor: 6.603

4.  The molecular function of kallikrein-related peptidase 14 demonstrates a key modulatory role in advanced prostate cancer.

Authors:  Thomas Kryza; Nathalie Bock; Scott Lovell; Anja Rockstroh; Melanie L Lehman; Adam Lesner; Janaththani Panchadsaram; Lakmali Munasinghage Silva; Srilakshmi Srinivasan; Cameron E Snell; Elizabeth D Williams; Ladan Fazli; Martin Gleave; Jyotsna Batra; Colleen Nelson; Edward W Tate; Jonathan Harris; John D Hooper; Judith A Clements
Journal:  Mol Oncol       Date:  2019-11-28       Impact factor: 6.603

5.  Kallikrein-Related Peptidase 6 (KLK6) as a Contributor toward an Aggressive Cancer Cell Phenotype: A Potential Role in Colon Cancer Peritoneal Metastasis.

Authors:  Hayet Bouzid; Feryel Soualmia; Katerina Oikonomopoulou; Antoninus Soosaipillai; Francine Walker; Khaoula Louati; Rea Lo Dico; Marc Pocard; Chahrazade El Amri; Natalia A Ignatenko; Dalila Darmoul
Journal:  Biomolecules       Date:  2022-07-19

6.  The PAR2 inhibitor I-287 selectively targets Gαq and Gα12/13 signaling and has anti-inflammatory effects.

Authors:  Charlotte Avet; Claudio Sturino; Sébastien Grastilleur; Christian Le Gouill; Meriem Semache; Florence Gross; Louis Gendron; Youssef Bennani; Joseph A Mancini; Camil E Sayegh; Michel Bouvier
Journal:  Commun Biol       Date:  2020-11-27
  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.